Last reviewed · How we verify
Inderal-LA
At a glance
| Generic name | Inderal-LA |
|---|---|
| Also known as | Propranolol, Propranolol ER capsules |
| Sponsor | Par Pharmaceutical, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study (PHASE4)
- Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma (PHASE2)
- Modafinil and Cognitive Function in POTS (EARLY_PHASE1)
- Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma (PHASE2)
- Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma (PHASE2)
- Beta-Blocker Influences on Inflammatory and Neural Responses to Stress (PHASE4)
- Pathophysiology of Orthostatic Intolerance (NA)
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inderal-LA CI brief — competitive landscape report
- Inderal-LA updates RSS · CI watch RSS
- Par Pharmaceutical, Inc. portfolio CI